Retatrutide, by Soma Chems , is receiving increasing attention as a novel method for metabolic management . This dual-action medication integrates the mechanism of a GLP-1 receptor stimulant and a GIP receptor agonist , intended to simply promote metabolic improvements but also target related metabolic factors. Initial patient trials have demonstra